Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q32 Bio Inc. Director's Dealing 2023

Nov 17, 2023

34891_dirs_2023-11-17_e7fc3994-1c40-47b0-82e0-01e39d6cda03.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-11-17

Reporting Person: Michaud Charles Jr (See Remarks)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2112 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option (Right to Buy) $15.58 2030-07-08 Common Stock (25000) Direct
Employee Stock Option (Right to Buy) $13.91 2031-02-16 Common Stock (9800) Direct
Employee Stock Option (Right to Buy) $2.71 2032-02-24 Common Stock (19300) Direct
Employee Stock Option (Right to Buy) $1.60 2033-02-23 Common Stock (49000) Direct
Restricted Stock Units $ Common Stock (544) Direct
Restricted Stock Units $ Common Stock (2144) Direct
Restricted Stock Units $ Common Stock (8000) Direct

Footnotes

F1: The option vests or has vested as to 25% of the underlying shares on June 8, 2021 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on June 8, 2024.

F2: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2021 such that the option will become fully vested on January 1, 2025.

F3: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

F4: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.

F5: The restricted stock units will vest and settle in full on January 1, 2024.

F6: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

F7: The restricted stock units will vest and settle as to 1,056 shares on January 1, 2024 and 1,088 shares on January 1, 2025.

F8: The restricted stock units will vest and settle as to one-third of the restricted stock units on each of the first three anniversaries of January 1, 2023.